Johnson & Johnson (JNJ) Current Deferred Tax Assets (2009 - 2015)
Johnson & Johnson (JNJ) posted Current Deferred Tax Assets of $3.6 billion for Q3 2015, down 3.14% sequentially from $3.7 billion in Q2 2015, and down 5.77% YoY from $3.8 billion in Q3 2014.
Johnson & Johnson (JNJ) Current Deferred Tax Assets (2009 - 2015) Analysis & Trends
Johnson & Johnson has reported Current Deferred Tax Assets for 7 years, with the latest figure at $3.6 billion in Q3 2015.
- Quarterly Current Deferred Tax Assets fell 5.77% year-over-year to $3.6 billion in Q3 2015, while the trailing twelve-month figure through Sep 2015 was $3.6 billion (down 5.77% YoY) and the FY2014 annual result came in at $3.6 billion, down 1.11% from the prior year.
- Current Deferred Tax Assets eased to $3.6 billion in Q3 2015 per JNJ's latest filing, from $3.7 billion in the prior quarter.
- Over five years, Current Deferred Tax Assets peaked at $4.1 billion in Q2 2014 and troughed at $2.2 billion in Q1 2011.
- A 5-year average of $3.2 billion and a median of $3.3 billion in 2012 frame the typical range for Current Deferred Tax Assets.
- The sharpest annual moves came in 2011 and 2012: Current Deferred Tax Assets retreated 20.37% in 2011, then surged 35.17% in 2012.
- Over 5 years, Current Deferred Tax Assets stood at $2.5 billion in 2011, then grew by 26.57% to $3.1 billion in 2012, then increased by 14.91% to $3.6 billion in 2013, then dropped by 1.11% to $3.6 billion in 2014, then increased by 1.09% to $3.6 billion in 2015.
- According to Business Quant data, Current Deferred Tax Assets over the past three periods registered $3.6 billion, $3.7 billion, and $3.5 billion for Q3 2015, Q2 2015, and Q1 2015 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 27, 2015 | 3.61 Bn |
| Sep 27, 2015 | 3.61 Bn |
| Jun 28, 2015 | 3.72 Bn |
| Jun 28, 2015 | 3.72 Bn |
| Mar 29, 2015 | 3.52 Bn |
| Mar 29, 2015 | 3.52 Bn |
| Dec 28, 2014 | 3.57 Bn |
| Dec 28, 2014 | 3.57 Bn |
| Sep 28, 2014 | 3.83 Bn |
| Sep 28, 2014 | 3.83 Bn |
| Jun 29, 2014 | 4.10 Bn |
| Jun 29, 2014 | 4.10 Bn |
| Mar 30, 2014 | 3.92 Bn |
| Mar 30, 2014 | 3.92 Bn |
| Dec 29, 2013 | 3.61 Bn |
| Dec 29, 2013 | 3.61 Bn |
| Sep 29, 2013 | 3.49 Bn |
| Sep 29, 2013 | 3.49 Bn |
| Jun 30, 2013 | 3.28 Bn |
| Jun 30, 2013 | 3.28 Bn |